Janney Montgomery Scott LLC Buys 5,148 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Janney Montgomery Scott LLC lifted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 44,500 shares of the medical research company's stock after acquiring an additional 5,148 shares during the quarter. Janney Montgomery Scott LLC owned 0.09% of Charles River Laboratories International worth $6,698,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. D1 Capital Partners L.P. bought a new stake in Charles River Laboratories International in the fourth quarter worth $172,752,000. Assenagon Asset Management S.A. grew its position in Charles River Laboratories International by 1,721.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock worth $85,811,000 after acquiring an additional 538,792 shares during the last quarter. Norges Bank purchased a new position in Charles River Laboratories International in the 4th quarter worth approximately $98,886,000. Wellington Management Group LLP lifted its position in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock valued at $752,508,000 after purchasing an additional 335,658 shares during the last quarter. Finally, Nomura Holdings Inc. bought a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $56,820,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Up 1.2%

Charles River Laboratories International stock traded up $1.84 during mid-day trading on Wednesday, hitting $150.24. The company had a trading volume of 747,365 shares, compared to its average volume of 1,018,573. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The stock's 50 day moving average price is $133.41 and its two-hundred day moving average price is $154.65. The company has a market capitalization of $7.38 billion, a PE ratio of -231.14, a price-to-earnings-growth ratio of 4.58 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The firm had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period in the previous year, the company earned $2.27 earnings per share. The firm's quarterly revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a research note on Wednesday, May 14th. Barclays boosted their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 price target for the company in a research report on Thursday, May 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $171.85.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).